What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)
Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.
How this was made
The 30-second read
Why it matters
The key new information is the raised Q2 2026 revenue range ($9.6M-$9.8M vs prior $8.5M-$9.5M) alongside management commentary that capital sales remain pressured while consumables are at record highs.
Market read
For a single-product-focused med-tech name, the updated Q2 revenue range is a direct near-term adoption signal, but the stock reaction suggests investors are still concerned about capital equipment demand durability.
What to watch
Traders may be underweighting the used UltraMIST availability and whether trade-in programs can convert into sustained new capital orders, not just near-term revenue smoothing.
Background
Sanuwave sells the UltraMIST directed-energy ultrasound system for wound care, with revenue split between capital sales and consumable applicators.
Ticker impact
Sanuwave guided Q2 2026 revenue to $9.6M-$9.8M, topping prior $8.5M-$9.5M range, while noting pressured capital sales and record consumables momentum.
Near-term volatility likely, with traders focusing on whether consumables momentum offsets ongoing capital system softness.
The article provides a concrete Q2 revenue range upgrade and operational drivers (capital sales pressure, trade-in support, record consumables), but it does not provide actual reported results or consensus comparisons, limiting conviction on magnitude/direction.
Market effects
Highlights demand bifurcation in wound-care med-tech between consumables (strong) and capital equipment (soft), which can influence read-across for similar device models.
Primarily US-focused revenue mix makes the update most relevant to domestic med-tech sentiment.
Limited direct global read-through since the article emphasizes US revenue and a single commercial product.
Counterpoint
The guidance raise may reflect timing or mix rather than a durable re-acceleration, especially with capital sales still pressured by customer financial constraints.
Key entities
- companySanuwave Health
NASDAQ-listed medical device company providing UltraMIST systems and consumable applicators for wound care.
- productUltraMIST system
FDA-cleared directed energy ultrasound/shockwave system used to treat acute and chronic wounds.
- executiveMorgan Frank
CEO cited regarding Q2 performance versus June guidance.
